Professor Angus Dalgleish
Principal of the Institute for Cancer Vaccines and Immunotherapy & Professor of Oncology
St George's University, London
Angus Dalgleish trained at University College Hospital. He trained in internal medicine and oncology at hospitals in Brisbane and Sydney. He returned to the UK in 1984 and undertook a thesis on retroviruses with Robert Weiss. He was appointed as Senior Clinical Scientist at the MRC Clinical Research Centre, Northwick Park, where he pursued his interests in HIV pathogenesis and the potential of Thalidomide to treat chronic disease. His suggestion that analogues of Thalidomide could lead to enhancement of the therapeutic activity and reduction of the side effects led to licensing of Revlimid (Lenalidomide) and Pomalidomide (Pomalyst) for myeloma and lymphoma by Celgene. He was awarded the Joshua Lederberg prize in 2011 in recognition of this work. Since 1991 he has been Professor of Oncology at St. George’s University of London. During this time he has focussed on the immunotherapy of cancer and has conducted numerous clinical trials involving a variety of vaccines and immunotherapy. Since 2011 he has been the Principal of the Institute for Cancer Vaccines and Immunotherapy. Reviewing the result of all the vaccine trials, it was clear that M. Vaccae (SRL-172) had the best 5 year survival outcome. This was resurrected and an improved agent, mycobacterium obuense (IMM-101), was selected for further trials, where it was shown to give a survival benefit in metastatic pancreatic cancer in a randomised trial. Melanoma patients who received IMM-101 and then relapsed were noted to have a higher response rate to checkpoint inhibitors (CPI’s), which has led to a formal study which is currently recruiting. Retrospective analysis of our trials has shown that non responders have high inflammatory markers compared to responders which has led to the identification of new anti-inflammatories such as LDN and the cannabinoids and IMiDs as potential enhancers of the current CPI’s.